CD8A and cancer: The boost in cancer cell killing in both the ABM and QSP contributes to a boost in Teff priming and expansion in the LN by providing more tumor neoantigens, creating a positive feedback between tumor neoantigen supply and anti-cancer effector CD8+ T cell generation.